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ABSTRACT
A present challenge in breast oncology research is to identify therapeutical 
targets which could impact tumor progression. Neurotensin (NTS) and its high affinity 
receptor (NTSR1) are up regulated in 20% of breast cancers, and NTSR1 overexpression 
was shown to predict a poor prognosis for 5 year overall survival in invasive breast 
carcinomas. Interactions between NTS and NTSR1 induce pro-oncogenic biological effects 
associated with neoplastic processes and tumor progression. Here, we depict the cellular 
mechanisms activated by NTS, and contributing to breast cancer cell aggressiveness.
We show that neurotensin (NTS) and its high affinity receptor (NTSR1) contribute 
to the enhancement of experimental tumor growth and metastasis emergence in 
an experimental mice model. This effect ensued following EGFR, HER2, and HER3 
over-expression and autocrine activation and was associated with an increase of 
metalloproteinase MMP9, HB-EGF and Neuregulin 2 in the culture media. EGFR over 
expression ensued in a more intense response to EGF on cellular migration and 
invasion. Accordingly, lapatinib, an EGFR/HER2 tyrosine kinase inhibitor, as well as 
metformin, reduced the tumor growth of cells overexpressing NTS and NTSR1. All 
cellular effects, such as adherence, migration, invasion, altered by NTS/NTSR1 were 
abolished by a specific NTSR1 antagonist. A strong statistical correlation between 
NTS-NTSR1-and HER3 (p< 0.0001) as well as NTS-NTSR1-and HER3- HER2 (p< 0.001) 
expression was found in human breast tumors.
Expression of NTS/NTSR1 on breast tumoral cells creates a cellular context 
associated with cancer aggressiveness by enhancing epidermal growth factor 
receptor activity. We propose the use of labeled NTS/NTSR1 complexes to enlarge 
the population eligible for therapy targeting HERs tyrosine kinase inhibitor or HER2 
overexpression.
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INTRODUCTION
The mortality rate of breast cancer has been 
stabilized due to early detection and constant progress in 
therapy. Nevertheless, breast cancer remains the leading 
cause of cancer-related deaths among women in most of 
the western countries [1,2]. The progression of tumors to 
a metastatic disease is the primary cause of death in most 
patients and the main target of cancer research.
The human epidermal growth factor receptor 
(HERs) signaling pathways have been shown to largely 
contribute to this process. The success of therapies 
employing HERs immunotherapy or tyrosine kinase 
inhibitors, while limiting the progression of the disease 
and extending the disease free survival time, demonstrates 
the contribution of HERs at the clinical level [3]. In breast 
cancer, where human epidermal growth factor receptor 2 
(HER2) gene amplication is detected in 25% of patients 
[4], a monoclonal antibody targeting HER2, trastuzumab, 
(Herceptin) significantly improves the survival of these 
patients [5]. Nevertheless, contribution of the HERs 
in breast cancer progression is complex, and studies 
have focused more specially on HER3/HER2 or HER2/
EGFR dimers. HER3 and HER2 overexpression and 
activation driven growth and metastasis are associated 
with a worse prognosis [6,8]. The availability of the 
EGFR inhibitors, proposed to patients in association 
with HER2 immunotherapy, has been a real benefit [9]. 
For example, patients with metastatic breast cancer, 
which had experienced progression under trastuzumab, 
found a benefit from the association of trastuzumab and 
Pertuzumab [5], a recombinant humanized monoclonal 
antibody binding to the HER2 dimerization domain 
and preventing dimerization of HER2 with other HER 
receptors (HER3, HER1, and HER4) [10]. More recently, 
investigations have focused on autocrine HERs activation 
in cells lacking HER2 amplification. This cellular context 
generates regulatory mechanisms involved in cancer 
progression and is suspected to induce drug resistance. 
These mechanisms remain to be clarified, and the 
identification of factors inducing this cellular context 
would help to better characterize and treat breast tumor.
Amongst the factors contributing to tumor 
aggressiveness, neurotensin (NTS) and its cognate high-
affinity receptor (NTSR1) have been shown to contribute 
to breast cancer progression [11,12]. High proportion of 
pro NTS in the blood is also correlated with a higher risk 
of breast cancer [13]. NTS and NTSR1 are concomitantly 
overexpressed in patients with breast cancer [14]. 
The deregulated expression profile of the NTSR1 was 
correlated with negative prognostic parameters such 
as tumor size, the number of invaded lymph nodes, 
Scarff, Bloom and Richardson’s histoprognostic grade, 
and patient mortality [14]. In corroborating clinical 
experiments, a direct effect of the neurotensinergic system 
on breast tumor growth in mice, and the anti-apoptotic 
property of NTS on breast cancer cellular models was also 
shown [15,16].
Under physiology, NTS, a 13 amino acids 
peptide, is mainly localized in endocrine N-cells of the 
gastrointestinal tract, where it regulates various functions 
such as inhibition of gut motility and gastric acid 
secretions, stimulation of pancreatic and biliary secretions 
and facilitation of fatty acids intake [17,19]. The effects of 
NTS are mediated by three subtypes of receptor. NTSR1 
and NTSR2 belong to the class A GPCRs [20] and exhibit 
high (sub-nanomolar) and low (nanomolar) affinity for 
NTS, respectively. NTSR3 or gp/95/sortilin is a single 
transmembrane domain receptor. The NTSR1 often 
overexpressed in tumors, activates many physiological 
effectors participating in cell proliferation, migration, 
invasion and remodeling of the actin cytoskeleton, like 
MAPK, focal adhesion kinase (FAK), and RhoGTPases. 
NTSR1 activation also transactivates the EGFR receptor in 
colonic, prostatic and pancreatic cancer cell lines [21,23].
We propose that a cross-talk occurs between 
neurotensinergic and the HER pathways in breast tumors 
which effects breast cancer progression. In this report, we 
analyzed this hypothesis, and showed that a NTS autocrine 
signaling loop dramatically accelerates the tumor growth 
and the metastatic progression of a poorly aggressive breast 
adenocarcinoma cell line. We analyzed the oncogenic 
cellular effects enhanced by NTS, and showed a possible 
synergic interaction between EGF and NTS, and observed 
a complete remodeling of HERs basal and activated 
profiles in cells under the constant stimulation by NTS.
RESULTS
The NTS-NTSR1 complex enhances tumor 
growth and metastasis emergence from breast 
experimental tumor
MCF-7 cells, which constitutively express NTSR1, 
were transfected with the neurotensin full length coding 
sequence to evaluate the influence of an autocrine 
neurotensinergic signaling loop on the tumorigenicity 
of the ER-positive breast cancer. Amongst the selected 
clones, two showed a differential NTS expression based on 
transcription levels the NTS high expressing clone, NTS-h, 
and the NTS low expressing clone, NTS-l (Figure 1A 
inset). The NTS expression levels were confirmed by 
quantitative RT-PCR in both clones, showing a 500-fold 
and a 4-fold NTS transcript’s induction for NTS-h and 
NTS-l, respectively as compared to the MCF-7 parental 
cells (Figure 1SA). High expression levels of NTS alter the 
cell morphology by reducing the size of the cytoplasm. The 
nucleocytoplasmic ratio is similar for NTS-l and parental 
cell lines (1/3.2 and 1/3.3 respectively) whereas the ratio 
decreases to (1/2.5) for NTS-h cells (Figure 1S B). The 
size of the nucleus remained similar for the three cell 
Oncotarget3www.impactjournals.com/oncotarget
lines (Fig 1S B). Immunofluorescent staining experiments 
show the sub-cellular localization of NTS (Figure 1S C - 
panels 1, 2, 3), and NTSR1 (Figure 1S C - panels 4, 5, 6). 
In wild type cells, no or an extremely weak NTS labeling 
is noted. In the NTS-l cells, NTS immunoreactivity is 
dispersed in small dots throughout the cytosol. The same 
pattern is observed in NTS-h cells with larger dots of 
stronger intensity due to the higher NTS expression level. 
In parallel, in MCF-7 cells, NTSR1 labeling is localized 
at the cell membrane, whereas an intense intracellular 
granular labeling of an endocytosed receptor is seen in 
NTS-h cell. NTS-l cells show a dual pattern of NTSR1 
localized both at the membrane and inside the cytoplasm.
To evaluate the influence of the NTS autocrine 
signaling loop on tumor growth, the MCF-7 parental 
line and the two NTS-overexpressing clones, NTS-l 
and NTS-h, were xenografted in the mammary fat pad 
of female athymic mice. Tumor growth rose with NTS 
expression levels (Figure 1A). The group bearing the 
MCF-7 cells began to develop tumors after 77 days to 
reach a small size of 108 ± 56 mm3 at day 105. During 
the same period of time mice bearing NTS-overexpressing 
cells developed much bigger tumors, with a volume of 483 
± 102 mm3 for NTS-l at day 105 and 1239 ± 251 mm3 for 
NTS-h at 91 days. The corresponding tumor weights were 
0.2 ± 0.1 g, 1.0 ± 0.2 g and 2.0 ± 0.2 g, respectively. None 
of the animals xenografted with MCF-7 cells developed 
metastases during the experiment (Figure 1B). On the 
contrary, metastases were observed in 41% of the NTS-l 
group and 76% of the NTS-h group. The metastases were 
preferentially found in the homolateral lymph nodes 
(24% and 59% respectively) and the lungs (35% and 
47% respectively). Furthermore, 18% of the animals in 
the NTS-h group also showed a metastatic spread in the 
controlateral lymph nodes reflecting a more advanced 
metastatic stage. Immunohistochemical slides representing 
examples of a lymph node, a lung, and a kidney metastatic 
lesion are shown in figure 1C.
The NTS/NTSR1 complex enhances EGFR, 
HER2, and HER3 expression and activation in 
breast cancer and tumoral cells
In order to identify the mechanisms underlying 
NTS induced growth and metastasis, we searched for 
the possible interrelation between NTS/NTSR1 complex 
and epidermal growth factor receptors (HERs). We first 
observed the amplification of HER2 and HER3 protein 
levels in tumors obtained after the xenograft of NTS-h 
and NTS-l cells, as compared to MCF-7 cells. In these 
cases, the membranes of the labeled tumoral cells was 
often thicker and more intense (Figure 2 A).
Analysis of NTS-l, NTS-h, and MCF-7 cellular 
protein content, showed an increase of 150–275% of 
EGFR, HER2, and HER3 (Figures 2B and C). This effect 
was confirmed by the stronger labeling of all three HER 
receptors by immunocytochemistry in NTS-l cells as 
compared to MCF-7 cells (Figure 2D). In NTS-l cells, 
EGFR is accumulated in clusters close to the nucleus, 
while in MCF-7, EGFR is at the membrane, HER2 
membrane labeling, and HER3 cytosol labeling are more 
intense in NTS-l than in MCF-7 cells (Figure 2D see 
white arrow). The specific NTSR1 antagonist, SR 48692, 
reduced HERs increases in NTS expressing cells, but 
not in wild type cells (Figures 2C and 2S A), validating 
the contribution of NTS/NTSR1 complex in this HERs 
overexpression. As HERs transcript levels were essentially 
the same in MCF-7 and NTS-l cells (Figure 2S B), HERs 
protein accumulation in the cells suggest that recycling 
and degradation are altered due to NTS exposure.
In parallel, an increase in the activation states for 
all three receptors was observed in NTS-l cells. The 
phosphorylation levels were enhanced up to 400 and 
500% for EGFR and HER3, respectively (Figures 2E 
and F), and was partially abolished by the antagonist SR 
48692 (Figure 2S C). Similar observations were made 
with NTS-h cells and a 200% increase was seen for the 
three receptors (not shown).
Subsequently, we searched for a possible EGFR and 
HER3 autocrine activation by the release of EGF “like” 
ligands from the cell membrane following a proteolysis 
process mediated by NTS. In the culture media from NTS-l 
cells, the amount of HB-EGF was twofold higher than 
MCF-7 cells. The presence of SR 48692 in the culture media 
abolished this increase (Figure 3 A). In the same vein, a 
stronger release of neuregulin 2 could be detected in the 
culture media of NTS-l cells compared to MCF-7 cells, and 
again counteracted by SR 48692 (Figure 3 B). The release 
of these specific ligands for EGFR and HER3 suggests 
an activation of metalloproteases due to NTS exposure. 
MMP9 transcripts increased (Figure 3 C) in NTS-l cells as 
compared to MCF-7, as was the case for MDA-MB 231 
cells [16]. In addition, MMP9 anchored at the membrane 
was activated, as a 180% increase of MMP9 released 
in culture media was detected in NTS-l as compared to 
MCF-7 cells and abolished by SR 48692 (Figure 3 D).
We confirmed the contribution of EGFR and HER2 
activation in NTS induced tumor growth by treating 
xenografted mice with NTS-h and lapatinib. Lapatinib 
inhibits the tyrosine kinase activity of both HER2 and 
EGFR. This property is currently used in breast cancer 
treatment. We confirmed that NTS-h cells do not carry 
the following EGFR active mutations: exon 19 deletion, 
exon 20 insertion, exon 18 Q719A, Q719C, Q719S and 
exon 21 L858R, L861Q point mutations. These cells do 
not possesses the HER2 exon 20 insertion, or the KRAS 
point mutations: G12D, G12S, G12C, G12R, G12A, 
G12V, G13D KRAS. Figures 4 A and B show that the 
tumor growth rate is reduced when mice are treated 
with lapatinib. The final tumor volume after 23 days of 
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treatment was 352.3 ± 87 mm3 for the control, and 134.5 
± 44.15 mm3 (p= 0.02 vs control) for lapatinib. We also 
tested metformin on our model. Metformin is suspected 
to provide anticancer effects in breast cancer and several 
clinical trials are currently under way [24]. In parallel, 
metformin was shown to disrupt the crosstalk between 
insulin receptor and NTS receptor in pancreatic cancer 
cells [25]. In addition to inhibiting the mTOR pathway, 
metformin prevents ERK activation induced by NTS and 
insulin [26]. In a breast cancer cellular model with NTS 
overexpression, metformin reduced the tumor growth with 
the same efficiency as lapatinib. No additional effects 
were detected when both drugs were employed. The final 
volumes were 135.9 ± 30.4 mm3 and 177.7 ± 51.3 mm3 
when animals were treated with metformin or both drugs, 
respectively (Fig 4 A and B). The tumor doubling time was 
in agreement with tumor volume with 11.7 ± 1.35 days, 
for controls. For lapatinib, metformin, and metformin + 
lapatinib double time cannot be calculated for because 
within the group 2 to 3 tumors shrank, the others grow 
very slowly. The absence of additional response suggested 
a common signaling cascade was targeted by both drugs.
Figure 1: NTS/NTSR1 complex enhanced experimental tumor growth generated in human breast cancer cell 
lines. (A) Experimental tumors were generated from the breast cancer cell line, MCF-7 and the NTS-overexpressing subclones. Comparative 
growth curves of MCF-7, NTS-h (high NTS expression) and NTS-l (low NTS expression) cells xenografted in 10, 20, and 25 mice, 
respectively. Tumor volumes were measured every week. Inset, NTS and NTSR1 transcript analysis from 200ng of MCF-7, NTS-h, and 
NTS-l total RNA. (B) Proportion of animals with metastases, and metastases distribution within organs and lymph nodes. (C) Typical H&E 
staining performed on paraffin sections of (left) invaded lymph node at 50X magnification, 200X magnification (black square) or 400X 
magnification (white square); (middle) lung metastasis at 400X magnification; (right) kidney metastasis at 400X magnification.
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The NTS/NTSR1 complex enhances  
pro-metastatic cellular effects
We evaluated the oncogenic cellular effects 
impacted by NTS. The basal growth capacity of MCF-7 
in an anchorage-independent context was doubled in the 
presence of NTS. In MCF-7 (Figure 5A), the colonies 
were organized in a spherical conformation around an 
inside lumen delimited by a single cell monolayer in wild 
type cells whereas, NTS-h or NTS-l the colonies were 
larger and the cells forming compact spheroids, filled up 
with cells (Figure 3S A).
Figure 2: NTS autocrine and paracrine regulation enhanced EGFR, HER2, and HER3 basal expression and activation 
in human breast cancer cell lines. (A) HER2 and HER3 immunohistochemistry performed on paraffin embedded tumors from 
mice xenograph with MCF-7, NTS-l or NTS-h. 200X magnification and computer enlargement of specific areas. (B) Breast cancer cells 
MCF-7, NTS-l and NTS-h, with the histograms representing intensity-based quantification of Western blot bands of basal total protein, 
EGFR, HER2, and HER3, using Morpho Expert software (Explora Nova, France). Values are expressed as the percentage of the control 
MCF-7 cells and are the mean ± SEM of 5 to 7 independent experiments. (C) Representative western blot analyses of EGFR, HER2, HER3 
and ERK 1/2 total protein from MCF-7 and NTS-l cells treated with 5x10-6 M SR 48692. (D) EGFR, HER2, and HER3 immunolabeling in 
MCF-7 and NTS-l cells treated after 48h of seeding. (E) Breast cancer cells MCF-7 and NTS-l, with the histograms representing intensity- 
based quantification of Western blot bands of phosphorylated protein, EGFR, HER2, and HER3. Values are expressed as the percentage of 
the control MCF-7 cells and are the mean ± SEM of 5 to 7 independent experiments. (F) Representative western blot analyses of Phospho 
EGFR, phosphoHER2, and Phospho HER3 protein from MCF-7 and NTS-l cells treated with DMSO or 5x10-6 M SR 48692 for 48h.
Oncotarget6www.impactjournals.com/oncotarget
Cell detachment is a pre-requisite in metastatic 
spreading. For this purpose, we studied the adhesion 
ability of our cellular models on various matrices. Cells 
were initially detached from their support and the kinetics 
of reattachment was evaluated. After 1 hour of seeding, 
the NTS-h cells displayed only 68% and 60% of the 
adhesion capacity on collagen (Figure 5 B) and matrigel 
(Figure 3S B) respectively, as compared to MCF-7. NTS-l 
cells displayed 55% and 52%, respectively. Interestingly, 
this decline in cellular adhesion ability stabilizes over 
time. At 48 hours of post seeding, the percentage of 
adherent cells is similar to those after 1 hour (Figure 5 B 
and 3S B). This suggests that NTS alters the basal cell 
adhesion capacities of the tumor cells.
We performed migration assays on type I collagen 
or matrigel supports, because migration requires cell 
interactions with the extracellular matrix. We developed an 
experimental procedure, in order to estimate the migration 
speed of the cells. As described in detail in the methods 
section, this procedure allows measuring the average 
distance covered by the cells within 48h, while preserving 
the matrix coating on the dishes. As shown in figure 5 C 
and 3S C, NTS expression significantly affects the basal 
migration speed of the NTS-l cells on both collagen and 
matrigel coated dishes. The migration speed on collagen 
was 2.50 ± 0.07 µm/h and 3.10 ± 0.09 µm/h (p < 0.0001; 
n=10) and on matrigel was 3.99 ± 0.21 µm/h and 5.31 
± 0.24 µm/h (p = 0.003; n=12) for MCF-7 and NTS-l, 
respectively. As EGFR expression was enhanced under 
NTS autocrine regulation, we inquired on the effect of 
EGF on cell speed migration. When cells were treated 
with EGF, a clear synergic effect between NTS and EGF 
Figure 3: EGF like ligands and metalloprotease released by NTS. (A) Amount of Hb-EGF (pg/ml), assayed in 0% FCS culture 
media of MCF-7, or NTS- l, cells. Cells were not treated, or treated for 24h with DMSO, 5x10-6M, SR 48692. Using Paired t test p = 0.0088 
between DMSO and SR 48692 NTS-l treated cells, n=4; with unpaired test p=0.03 between MCF-7 and NTS-l, n=5. (B) Amount of NGR2 
(pg/ml) assay in 0% FCS culture media of MCF-7 or NTS-l cells not treated or treated for 48 h with DMSO, 5x10-6M SR 48692. Using 
Paired t test p = 0.005 between DMSO and SR 48692 NTS-l treated cells, n=5; with unpaired test p=0.016 between MCF-7 and NTS-l, n=4. 
(C) MMP9 transcript analysis of total RNA from MCF-7, and NTS-l treated with DMSO or 5x10-6 M SR 48692 for 48h. (D) Amount of 
MMP9 (pg/ml) assay in 0% FCS culture media of MCF-7 or NTS-l cells not treated or treated for 48 h with DMSO, 5x10-6M SR 48692. 
Using Paired t test p = 0.005 between DMSO and SR 48692 NTS-l treated cells, n=5; with unpaired test p=0.003 between MCF-7 and 
NTS-l, n=5.
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was observed. The NTS-l cells migrate 38% and 42% 
faster when treated with EGF on collagen and matrigel 
respectively, compared to EGF-treated MCF-7 cells 
(Figure 5 C and 3S C). In order to confirm the contribution 
of the NTS-NTSR1 complex in this synergic effect, 
MCF-7 and NTS-l were treated with EGF and the NTSR1 
specific antagonist SR 48692. As shown in figure 5 C and 
3S C, this treatment had no effect on the EGF-induced 
migration of MCF-7 on collagen and matrigel, whereas, 
SR 48692 inhibited the acceleration of the migration speed 
in the EGF-treated NTS-l cells. Specific PKC and PLC 
inhibitors were applied and clearly abolished the synergic 
effect of NTS and EGF observed in NTS-l cells. In the 
parental cells, EGF’s contribution to the migratory effect 
was insensitive to these inhibitors although the basal 
migration speed did increase in matrigel matrix (Figures 
5 D and 3S D). As control, a specific inhibitor of EGFR, 
the AG1478, completely abolished the EGF-induced 
migration in both MCF-7 and NTS-overexpressing cells 
(Figure 5 D and 3S D).
The invasiveness properties of NTS-overexpressing 
cells, was studied using a 3 dimensional collagen invasion 
assay. Results are expressed as the invasion index 
corresponding to the number of invading cells related to 
the number of total seeded cells. The introduction of NTS 
expression into MCF-7 cells induced a small increase in 
invasiveness properties (Figure 5 E). However, EGF-
induced invasion doubled in NTS-overexpressing cells 
(20% invasion index) as compared to MCF-7 (10% invasion 
index). The induction of invasiveness was inhibited by PKC 
inhibitors only in NTS-overexpressing clones, suggesting 
dependence of this effect on GPCR activation.
The synergic effects of NTS and EGF on cellular 
migration and invasion suggest that a new pattern of HER 
heterodimers, with a higher EGF response potency, is 
generated in the cells. When cells were stimulated with 
Figure 4: NTS/NTSR1 expressing tumors response to EGFR/HER2 inhibitor treatments. (A) NTS-h cells were inoculated 
in the left mammary gland of the mice. Here is shown an example of a mouse from each group after 23 days of treatment. (B) Tumor 
growths generated by NTS-h cells treated for 23 days with sesame oil 6% DMSO, or 75 mg/kg lapatinib, or 200 mg/kg metformin, or both. 
At day one, 7 mice per group were randomized on tumors size reaching approximately 95 mm3.
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EGF, the amount of phosphorylated proteins EGFR, 
HER2, and HER3 in the NTS-overexpressing cells is 
higher than the phosphorylated proteins in wild type cells, 
with an increase of 290, 190, and 275%, respectively as 
compared to MCF-7 EGF treated cells (Figure 6 A and B).
Figure 5: NTS autocrine and paracrine regulations enhanced oncogenic cellular effects on EGF-induced migration and 
invasion. (A) Number of colonies formed on semi-solid medium after 12 days expressed as the percentage of MCF-7 cells. (B) Adhesion 
assays were performed on type I collagen supports. After 1h or 48h of seeding, cells were gently washed and the remaining attached cells 
were quantified by spectrophotometric analysis of crystal violet staining. Results represent the mean optic density ± SEM of 4 experiments. 
(C) Speed of migration on type I collagen of MCF-7 and NTS-l cells, control or treated with EGF (10 ng/mL), in the presence or not of 
SR 48692 (5x10-6 M). Results represent the mean ± SEM of 9 to 10 independent experiments. (D) Speed of migration on type I collagen 
of MCF-7 and NTS-l cells control or treated with EGF (10 ng/mL), in the presence or not of the PKC-inhibitor Gö6976 (5x10-8M) or the 
PLC-inhibitor U73122 (5x10-6 M) Results represent the mean ± SEM of 4 independent experiments. Results represent the mean ± SEM of 
3 to 4 experiments. Student-Newman-Keuls Multiple Comparisons Test was performed on the data : ***P<0.001,**P<0.01, and *P<0.05. 
(E) Synergism between NTS and EGF on invasion in a type I collagen invasion assay. Cells were seeded on the top of a type I collagen 
gel and treated with EGF (100 ng/mL) in the presence or absence of Gö6976 (5x10-8 M). Results represent the mean ± SEM of 3 to 
4 experiments.
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Overexpression of NTS and NTSR1 correlates 
with HER2 and HER3 overexpression in breast 
human tumors
Co expression of NTS, NTSR1, HER2 and HER3 
was analyzed in breast cancer tissue microarrays (TMA). 
Seven TMAs containing 269 samples each, was scored 
from 0 to 3 according to the labeling intensity and the 
proportion of stained cells. Correlations between the 
expression of NTS/NTSR1 complex and the expression of 
HER2 and/or HER3 were evaluated. We considered that 
a score of 2 and 3 indicate the overexpressed condition, 
and consequently we performed contingent’s analysis on 
these combined scores. Results are summarized in table 1. 
NTS and NTSR1 were found in 23% of the samples, 
in agreement with our previous studies [14], whereas 
HER2 and HER3 were found in 28% and 53% of the 
samples, respectively. Amongst this NTS-NTSR1 positive 
population a higher proportion overexpressed HER3 
(16%) than HER2 (7%). HER3 expression was positively 
associated with those for NTS and NTSR1 (OR= 19.073, 
95% Confidence Interval [13.633-26.684], p<0.0001). In 
contrast, no significant relation between HER2 and NTS/
NTSR1 was found. Only 5% of the samples overexpressed 
the four markers, nevertheless HER2 and HER3 
expressions remained strongly significantly associated 
to NTS/NTR1 expression (OR = 12.117 95% Confidence 
Interval: to [7.121-20.618], p<0.0001). It should be noted 
that an absence of correlation between high expression of 
HER2 and HER3 was detected. Two examples of the same 
tumor sample labeled for the four markers are shown in 
figure 7.
DISCUSSION
The organization of tumor cell signaling networks 
evolves with accumulation of genetic and epigenetic 
alterations in connection with the local stroma, vessels 
and immune system. Identifying factors which contribute 
and predict tumor aggressiveness are means to understand 
how the progression of the disease evolves across 
individuals. Unfortunately, the biological and clinical 
Figure 6: Synergy between NTS and EGF to activate EGFR, HER2, and HER3. (A) Breast cancer cells NTS-l or MCF-7, 
with the histograms representing intensity- based quantification of Western blot bands of phosphorylated protein, EGFR, HER2, and HER3 
treated for 10 min with 10ng/ml EGF. Values are expressed as the percentage of the EGF treated MCF-7 cells and are the mean ± SEM 
of 5 independent experiments. (B) Representative Western blot analyses of phosphoEGFR, phosphoHER2, phosphoHER3 and actin from 
MCF-7 and NTS-l cells treated or not with 10ng/ml EFG for 10 min.
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validation of these factors is difficult because tumors are 
often heterogeneous and their molecular characteristics 
evolve over time. In addition to the clinical parameters, 
genetic alterations on key genes provide additional 
information on disease outcome. These genetic alterations 
can be modulated by regulatory mechanism which may 
cause changes to the amplitude of cell aggressiveness 
within the tumor. While genetic alterations acquired by 
tumors are irreversible, their regulatory process can be 
de-programmed to restore a tumor phenotype to a less 
aggressive and more differentiated form.
In this article we show that the NTS/NTSR1 
complex enhances tumor aggressiveness (tumor 
growth and metastasis emergence) by enhancing HERs 
expression, and their activation by the release of specific 
EGFR and HER3 ligands. This concept can be extended 
to other tumors, as we observed similar results in lung 
cancer cells and subsequent experimental tumors [27]. 
In lung cancer cells all three receptors (but mainly HER2 
and HER3) are over expressed under NTS autocrine 
regulation. EGFR and HER3 activation occurred with 
HB-EGF and NGR1 as well as MMP1 released from the 
cells [51].
In breast cancer cells, NTSR1 activation alters many 
cellular effects having oncogenic characteristics including 
proliferation, survival, adherence, migration and invasion, 
with a synergic effect between NTS and EGF on cellular 
migration and invasiveness. This latter point may explain 
the exacerbation of the metastasis process seen due to 
NTSR1 activation. Synergy between NTS and EGF was 
Figure 7: NTS, NTSR1, HER2, and HER3 immunohistochemistry on breast and lung cancer tumors. Two examples of 
positive labeling scored 2 or 3 for NTS, NTSR1, HER2, HER3 from breast tumor TMA, labeling was performed on consecutive slides. 
100X magnification.
Table 1: Contingent analysis for NTS, NTSR1, HER2 and HER3 expression on samples from breast 
cancer tissue microarray
NTS NTSR1 HER2 HER3
n total 1408 1347 1268 1410
Positive n (%) 1029 (73) 375 (28) 361 (28) 753 (53)
NTS, n (%) 301 (23) p<0.0001 274 (22) 599 (43) p = 0.006
NTSR1, n (%) 102 (8) 244 (19) p<0.0001
HER2, n (%) 218 (18)
NTS & NTSR1, n (%) 85 (7) 204 (16) p<0.0001
NTS & NTSR1 & 
HER2, n (%) 62 (5) p<0.0001
n total= number of sample readable; Positive = number of sample scored 2 or 3; P = Fisher's Exact Test
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previously described on DNA synthesis in primary adult 
rats’ hepatocytes [28], and the regulation between these 
two factors appears to be independent of oncogenic 
characteristics of the cells. EGF was detected in normal 
and tumoral breast tissues, with a higher expression found 
in normal tissues adjacent to tumor [29]. We previously 
showed that NTS is expressed in normal breast epithelial 
cells. Its expression is regulated by estrogen [14]. The 
synergy between NTS and EGF may therefore occur 
during the breast carcinogenesis.
Our data showed that under NTS stimulation, 
EGFR, HER2 and HER3 are up-regulated and intrinsically 
activated. This over expression was not associated with 
gene transcriptional or post-transcriptional activity, 
suggesting that NTS induced a new equilibrium in HERs 
cellular traffic and a new pattern of HERs formed after 
stimulation. HERs internalization pathways depend on the 
expression of ligands and/or their receptors [30,31]. Under 
physiological conditions (low concentration of ligands 
and moderate EGFR expression <200 000/cell), EGFR 
internalization is dependent on clathrin coated pits, with 
a half-life of 6-10 hours. However, under conditions of 
receptor overexpression or high concentration of ligands, 
the clathrin pathway becomes saturated, and the complex 
(ligand-receptor) is internalized with a slow kinetics in a 
clathrin independent pathway. Under these conditions, the 
half-life can reach 24 hours [32,33].
In cells overexpressing HER2, receptors are 
mainly localized at the cell membrane, indicating that 
overexpression of HER2 does not lead to accelerating 
its endocytosis [34].The HER2 heterodimerization 
with EGFR influences the endocytosis pathway for 
both receptors. Treatment by EGF of cells expressing 
low HER2, resulted in HER2 down-regulation [35]. In 
contrast, EGFR activation in cells overexpressing HER2, 
does not affect the membrane expression of HER2 or its 
degradation [34,36]. In addition, overexpression of HER2 
had a dominant-negative effect on the down regulation 
of stimulated EGFR, and stabilized both receptors by 
altering autophosphorylation patterns [34,37]. HER2 
overexpression may also prevent EGFR internalization by 
clathrin-dependent endocytosis, and it’s re-directed from 
the degradation to the recycling pathway [36,38,39].
The activation of HER3 leads to its internalization 
and its down regulation. However, HER3 internalization 
is slower than EGFR internalization [40]. In addition, 
HER3 is inefficiently sorted to the degradation pathway, 
apparently due to the lack of the C-terminal domain, 
which contains patterns used for targeting to lysosomes 
[41,42]. It has also been suggested that neuregulins do not 
guide HER3 to degradation due to the early dissociation of 
complexes (ligand-receptor) in endosomes [41]. In these 
situations the stabilization of HERs cells are independent 
of gene transcription, activation and amplification, as in 
the case for NTS.
Associated with HERs regulation, we also 
observed an increase of NRG2 and HB-EGF secretion 
by NTS mediated by MMP activation. The release of 
these growth factors caused the concomitant activation 
of HER3 and EGFR. EGF “like” ligands are largely 
implicated in breast cancer progression, yet, most reports 
have only studied the expression of ligands specific to 
EGFR, or those specific to HER3. For example, in one 
case a 10 fold increase of HB-EGF in cancer tissues was 
reported, and in another a high proportion of the four 
neuregulins and major isoforms were expressed in the 
cytoplasm of DCIS and IDC of the breast [29,43,44]. 
In both cases, deleterious effects of growth factors 
are often in HER2 overexpressing cells, indicating 
that EGFR/HER2 and/or HER3/HER2 dimers are 
related to biological aggressiveness [29]. Globally, the 
overexpression of both HER2 and HER3 participates in 
the stabilization of the HERs dimer, and subsequently 
the sustained activation of the HERs, and the survival 
pathway. By enhancing the overexpression and 
activation of EGFR, HER2 and HER3, the NTS/NTSR1 
complex becomes an upstream factor that modulates this 
regulatory mechanism.
In agreement with in vitro studies, tumor growth 
induced by NTS/NTSR1 can be restrained by a specific 
tyrosine kinase inhibitor EGFR and HER2, lapatinib. The 
cascade of biological events from the interaction between 
NTS and NTSR1 to the activation of HERs receptor 
appears to be a major contributor to rapid cancer cell 
growth.
This cascade is inhibited by metformin, known to 
interfere with activated mTOR and ERK pathway [26,45]. 
The lack of additional effects from the combination of 
the two drugs suggests that consecutive cellular events 
lead to increase tumor aggressiveness by NTS. We 
previously showed that sustained NTSR1 activation 
generated a permanent PKC dependent activation of ERK 
signaling [46]. It is therefore coherent that metformin 
and other ERK or PKC inhibitors counteract the same 
NTS oncogenic cellular effect. PKC appears to be a 
central signaling hub to generate cell aggressiveness by 
NTS/NTSR1 through the sustained overexpression and 
activation of HERs.
Experimental tumors report the tumorigenic 
performance of single cell lines or clones. Nevertheless, 
heterogeneity is an important characteristic of human 
tumors. For instance, we found that in 35% of patient with 
IDC, NTSR1 was expressed in at least 80% of tumoral 
cells, and only 20% of patients express high level of 
NTSR1 and NTS [47]. In human tumors, NTS and NTSR1 
are expressed in cells clusters with diverse sizes. Tumoral 
cells with potential aggressiveness characteristics could be 
detected with NTS/NTSR1 labeling, and specific treatment 
could be proposed accordingly. Lapatinib is proposed in 
a second line of treatments, in combination with other 
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drug in advanced or metastatic breast cancers whose 
tumors overexpress HER2. Our results suggest that a more 
restrained (or targeted) population, can be determined by 
taking into account NTS and NTSR1 co expression. The 
resulting subpopulation will provide a significantly better 
performance for this drug.
CONCLUSION
The activation of the neurotensinergic system in 
breast tumors induces the overexpression of the EGFR, 
HER2 and HER3 receptors and their concomitant autocrine 
activation. The presence of this regulatory mechanism 
would have a significant impact on cancer progression in 
tumor cells by accelerating the process of metastasis. It 
also modulates the response to tyrosine inhibitor HER2 
and EGFR therapy. NTS/NSTR1 overexpression in breast 
cancer cells creates a tumoral context for EGFR tyrosine 
kinase inhibitor responsiveness, and therefore a new 
population of patients would be eligible to these specific 
tyrosine inhibitors.
MATERIALS AND METHODS
Cell culture procedure
The human breast adenocarcinoma cell line MCF-
7 and the corresponding NTS–overexpressing clones, 
NTS-h (high level of NTS) and NTS-l (low level of 
NTS), were grown at 37°C, in a humidified atmosphere 
of 5% CO2, in DMEM supplemented with 10% fetal 
calf serum, 2 mM glutamine and G418 0.5 mg/mL 
(Invitrogen™).
Tumor xenografts
3 millions cells (MCF-7, NTS-h, NTS-l) resuspended 
in Matrigel (BD Biosciences) were then inoculated in 
the right mammary gland of the mice. Tumor growth 
was induced by a daily intra-peritoneal injection of 
2µg estradiol per mouse. Tumors, axillary and inguinal 
lymph nodes, lungs, liver and bones (vertebra, sternum) 
were taken, weighed and fixed in formol or frozen. All 
the procedures were in accordance with the “Guide of 
the Care and Use of laboratory Animals”. Institutional 
Review Board approval was obtained by «Le Comité 
d’Ethique pour l’Expérimentation Animale Charles 
Darwin # Ce5/2010/049 ». For lapatinib experiments 
NTS-h cells were inoculated in the left mammary gland 
of the mice. 51 days after injection, 4 groups of 7 mice 
were randomized as follows : 95.9 ± 14.57 mm3 for 
control group, 94.5 ± 15.0 mm3 for lapatinib group, 91.5 ± 
14.09 mm3 for metformin group and 95.6 ± 12.20 mm3 
for lapatinib and metformin group. Mice were treated for 
21 days per os, with sesame oil containing 6% DMSO, or 
75 mg/kg lapatinib, or 200 mg/kg metformin or both.
Western blots
Samples in Laemmli buffer were loaded on 10% 
SDS-PAGE and transferred to PVDF membranes. 
Membranes were exposed to primary antibody overnight. 
Total anti-EGFR (1:500), anti-phospho-EGFR (1:500), 
anti-phospho-HER2 (1:500), anti-HER3 (1:2000), anti-
phospho-HER3 (1:1000), anti-ERK 1/2 (1:2000) were 
from Cell Signaling Technology®. Total anti-HER2 
(1:2000) were purchased from Neomarkers and anti-βactin 
(1:50000) from Sigma®. Secondary anti-rabbit (Santa 
Cruz Biotechnology) or anti-mouse (Sigma®) antibodies 
conjugated to HRP were used at 1:2000 dilutions for 
1h at room temperature and visualized by enhanced 
chemiluminescence (GE Healthcare®). See details in 
supplementary information.
Adhesion assays
The assay was performed in 96-wells plates coated 
or not with 50 µg/mL of type I collagen (Sigma®) 
overnight at 4°C or with 1:10 diluted-growth factor 
reduced Matrigel (BD Biosciences®) for 1 hour at 37°C. 
Cells were harvested with PBS containing 0.5 mM 
EDTA for 20 min at 37°C, pelleted and suspended in 
adhesion buffer (DMEM, 15 mM HEPES, 1.2g/L sodium 
bicarbonate, 0.2% BSA). 5x104 cells per well were seeded 
and incubated at 37°C for 1 or 48 hours. Wells were 
washed with culture medium and adherent cells fixed 
with 5% paraformaldehyde for 45 min, then colored with 
0.1% cristal violet during 30 min at room temperature. 
Cells were subjected to 30 min lysis in 1% SDS under 
agitation. Absorbance at 570 nm was determined by 
spectrophotometric measures and correlates with the 
number of adherent remaining cells.
Anchorage-independent growth assay in soft 
agar
Colony growth assays were performed by seeding 
on the top of a 0.6% low gelling temperature agarose layer, 
5x103 cells in 0.5 mL of cultured medium containing 0.3% 
agarose solution ± EGF (10 ng/mL). Culture medium 
and EGF were replenished every 2-3 days. Cells were 
incubated at 37°C for 12 days and colonies ≥ 50 µm were 
counted in the whole well.
Cell migration assays
12 wells-culture plates were coated with type I 
collagen or Matrigel as mentioned in adhesion assay. 
1x105 cells were plated for 4 hours in an 8 mm-cloning 
ring placed in the center of the well to form a confluent 
circle of monolayer cells. The cylinder was removed and 
cells grow for 16 hours. Cells were then treated in serum-
free medium ± EGF (10 ng/mL) in the presence or absence 
of various cell signaling inhibitors. Four pictures were 
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acquired per well at the initial time of treatment and 48 
hours later for comparison with an inverted microscope 
at 200X magnification. Migration speed was determined 
using the Morpho Expert software (Explora Nova) and 
was expressed as the average cells covered distance 
divided by the experimental duration (µm/h). Presented 
results are expressed in percentage of the non-treated 
condition.
Collagen invasion assays
Invasion potential was evaluated by a single-cell 
collagen invasion model, extensively described [48]. 
Briefly, 6-wells plates were coated with 1.25 mL of a 1 
mg/mL collagen type I solution, allowed to gel for at least 
1 hour at 37°C in a humidified atmosphere containing 
10% of CO2. 2x10
5 viable single-cells, obtained by mild 
enzymatic dissociation with trypsin/EDTA solution and 
filtration, are seeded on the top of the gel in presence or 
not of EGF (100 ng/mL) and/or Gö6976 (4x10-8 M) for 
24h. Invasion index (cells with invasive extensions versus 
total number of cells × 100) was determined by counting 
the number of invading and non-invading cells present 
in 10 to 15 random fields of an inverted phase-contrast 
microscope.
ELISA (Enzyme-linked immunosorbent assay)
Cells were seeded at 4X106 cells in 100 mm dish 
in culture media. The next day media was changed to 
4.5 mL of serum free media for 48h. To assay Hb-EGF 
and NRG-2, the media were concentrated with dialysis 
tube (7 Spectra / Por ® Dialysis Membrane). In all 
samples Protease Inhibitor Cocktail P8340 [1:100] were 
added. MMP9, HB-EGF and NRG2 released in the culture 
media were assayed by ELISA kits (DuoSet®ELISA 
Development System, and USCN Life Science Inc.).
RNA extraction and RT-PCR
Total RNA was extracted by the acidic phenol/
chloroform guanidine thiocyanate method as documented 
by [49,50]. Detailed are described in supplementary 
information.
Immunohistochemistry
Procedure is detailed in supplementary information. 
The slides were incubated at 4°C overnight with primary 
antibody included anti-NTS (1:200, SC-20806, Santa Cruz 
biotechnology®), and anti-ErbB3 (1:50, NCL-c-erbB-3, 
Novocastra™), anti-NTSR1 (1:100; SC-7596, Santa Cruz 
Biotechnology®) and anti-ErbB2 (1:400, A0485, Dako) 
was incubated at room temperature for 1hour and 30 
minutes respectively. The levels of staining were scored 
based on staining intensity within the tumor sample, with 
weak as 1, moderate as 2, strong as 3.
Patients
We studied 499 specimen from patients operated 
for breast cancer in 2008 in Algeria. The average patient 
age was 51.1 ± 11.7 years. The sizes of the tumors were 
36.3 ± 21.7 mm. The SBR histoprognostic grading 
was 6% grade I, 63% grade II and 31% grade III (See 
supplementary information). Investigation has been 
conducted in accordance with the ethical standards and 
according to the Declaration of Helsinki and according 
to Algerian guidelines and has been approved by the 
authors' institutional review board from CPMC. Data were 
analyzed anonymously.
Statistics
Statistical analysis was carried out using test 
Student’s t-test or Student-Newman-Keuls Multiple 
Comparisons Test : ***p<0.001,**p<0.01, and *p<0.05. 
For contingency analysis Fisher's Exact Test was applied. 
The Odds ratio was performed using the approximation 
of Woolf.
ADDITIONAL METHODS
Transfection procedure
Following the manufacturer’s instructions, a 
pCDNA3.1 plasmid encoding the large fragment of rat 
neurotensin ou neurotensin full length coding sequence 
was transfected in MCF-7 cells using the Lipofectamine 
Plus Reagent (Invitrogen™). Briefly, 0.8x106 cells were 
plated in 60 mm-Petri dishes and were allowed to grow 
24 hours before transfection. 2µg of DNA were complexed 
together with the Plus Reagent and the Lipofectamine 
Reagent to form transfection complexes which were 
incubated during 4 hours on the cells. Complete medium 
was then added to reach a 10% final fetal calf serum 
concentration. 24 hours later, cells were harvested 
and placed in fresh culture medium. Selection was 
performed 2 days after transfection with 1mg/mL of G418 
(Invitrogen™). Stable clones were obtained by cloning 
dilution and screened by classic RT-PCR and real-time 
PCR for the NTS expression level.
Western blot
2x106 cells were grown for 72h then serum-
starved for 48h in a phenol red-free medium in presence 
or absence of different concentrations of 5x10-6 M SR 
48692 and 25x10-9 M MMP9 inhibitor (Calbiochem®). 
For EGF treatments, cells were then treated 15 min with 
EGF (10 ng/mL) lysed (20 mM Tris pH 8.0, 150 mM 
NaCl, 5 mM MgCl2, 0,5% NP40, 0,5% glycerol, 1 mM 
PMSF, protease and phosphatase inhibitor cocktail) at 4°C 
for 30 min. Samples in Laemmli buffer were loaded on 
10% SDS-PAGE and transferred to PVDF membranes. 
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Saturation was performed 30 min at room temperature 
in 5% non-fat dry milk in TBS 0.1% Tween 20. Primary 
antibodies were incubated overnight at 4°C according to 
the manufacturer’s instructions. Total anti-EGFR (1:500), 
anti-phospho-EGFR (1:500), anti-phospho-HER2 (1:500), 
anti-HER3 (1:2000), anti-phospho-HER3 (1:1000), anti-
ERK 1/2 (1:2000) were from Cell Signaling Technology. 
Total anti-HER2 (1:2000) were purchase from Neomarkers 
and anti-βactin (1:50000) from Sigma. Secondary anti-
rabbit (Santa Cruz Biotechnology®) or anti-mouse 
(Sigma®) antibodies conjugated to HRP were used at 
1:2000 dilutions for 1h at room temperature and visualised 
by enhanced chemiluminescence (GE Healthcare®).
RNA extraction
Total RNA was extracted by the acidic phenol/
chloroform guanidine thiocyanate. Two cycles of 
phenol-chloroform extraction (pH 4.7) were preceded 
by two ethanol precipitations in GTC buffer (4 M 
Guanidium Thiocyanate, 50 mM Tris pH 7.5, 10 mM 
EDTA pH 8.0, 30% N-lauroylsarcosine sodium salt, 1% 
β-mercaptoethanol) and followed by a final extraction with 
chloroform-isoamyl alcohol 25:1 (v/v). Two final ethanol 
precipitations in acetic acid and NET buffer (150 mM 
NaCl, 15 mM Tris-HCl pH 7.5, 1 mM EDTA) were 
successively performed. After washing in 70% ethanol, 
pellets were resuspended in 20 µL of sterile deionized 
diethyl pyrocarbonate-treated water and titrated by 
spectrophotometric measure of the absorbance at 260 nm.
RT-PCR and quantitative PCR
1µg of total RNA was subjected to reverse 
transcription, during 1 hour at 37°C, using 1 µg of 
nonspecific hexameric random primers dN, 1mM dNTP, 
10 mM dithiothreitol, 24 units RNaseOUT and 200 units of 
M-MLV-RT enzyme (Invitrogen). The PCR amplification 
was performed on 1:10 (v/v) of the 1:10-diluted reverse 
transcription reaction using 0.2 mM dNTP, 2.5 mM MgCl2 
and 1 unit of Thermostart Taq DNA polymerase (Thermo 
Scientific), and 25 pmol of each specific primer :
NTS (5’-CAGCTCCTGGAGTCTGTGCT-3’ and 
5’-GAGTATGTAGGGCCTTCTGGG-3’)’
NTSR1 (-5’-CGTGGAGCTGTACAACTTCA-3 
and 5’-CAGCCAGCAGACCACAAAGG-3)
HER3 (5’-ATGGGGAACCTTGAGATTGTGCT-3’ 
and 5’-ACAGCTTCTGCCATTGTCCT-3’)
EGFR 
(5’-TTTCGATACCCAGGACCAAGCCACAGCAGC-3’ 
and 5’ AATATTCTTGCTGGATGCGTTTCTGTA-3’)
HER2 (5’-GTGCTAGACAATGGAGACC-3’ and 
5’-CACAAAATCGTGTCCTGGTAGC-3’)
18S (5’-AGGAATTGACGGAAGGGCAC-3’ and 
5’-GTGCAGCCCCGGACATCTAAG-3’)
36B4 (5’-GTGCAGCCCCGGACATCTAAG-3’ and 
5’-GATTGGCTACCCAACTGTTG-3’)
Semi-quantitative amplification was performed 
in a DNA thermal cycler 9700 (Perkin Elmer Applied 
Biosystem), and Maxima SYBRGreen qPCR Master Mix 
(Fermentas) in a Mx3000P qPCR system (Stratagene) was 
used for quantitative PCR.
Patients
We studied 499 specimens of patients operated 
for Breast cancer in 2008 in Algeria. The average of 
patient age was 51.1 ± 11.7 years. The size of the tumor 
was 36.3 ± 21.7 mm. The SBR histopronostic grading 
was 6% grade I, 63% grade II and 31% grade III. The 
Subtypes were distributed as followed : 75.9% Invasive 
ductal carcinomas, 10% invasive lobular carcinomas, 
2.2% Mucinous carcinomas, 1.20% Invasive papillary 
carcinomas, 1.6% invasive micropapillary carcinomas, 
0.40% Invasive metaplasic carcinomas, 0.60% 
metaplasic carcinomas, 3.4%, invasive ductal and 
lobular carcinomas, 1.20% mixte Mucinous and ductal 
carcinomas, 3% mixte ductal and metaplasic carcinomas 
and 0.4% others. For TMA Three sample per specimen 
were analyzed.
Immunohistochemistry
Deparaffinized TMA sections (4 µm) were 
subjected to heat-induced epitope retrieval in citrate 
buffer (pH 6.0). The sections were labeled for the target 
proteins using the avidin-biotin-peroxidase complex 
method. The slides were incubated at 4°C overnight with 
primary antibody included anti-NTS (1:200, SC-20806, 
Santa Cruz biotechnology®), and anti-ErbB3 (1:50, 
NCL-c-erbB-3, Novocastra™), anti-NTSR1(1:100; SC-
7596, Santa Cruz Biotechnology®) and Anti-ErbB2 
(1:400, A0485, Dako) was incubated at room temperature 
for 1hour and 30 minutes respectively. These slides were 
then incubated with appropriate biotinylated secondary 
antibodies, NTS (Trekkie Biotinylates rabbit link, 
Biocare medical®), NTSR1 (Biotinylated anti-goat IgG, 
Vector laboratories, Inc), ErbB3 (Trekkie Biotinylates 
mouse link, Biocare medical®). The antigen-antibody 
complex was revealed with avidin-biotinperoxidase 
complex, according to the manufacturer's instructions, 
NTSR1 (Vectastain ABC Kit, Vector laboratories, 
Inc.), NTS and ErbB3 (Trekavidin-HPR label, Biocare 
medical®). ErbB2 was biotinylated and revealed with 
the NovoLink™ Polymer Detection System (Leica®). 
NTSR1 and ErbB2 staining were done with diamino-
benzidine tetrahydrochlorid, NTS and ErbB3 were done 
with aminoethyl carbazole. All slides were counterstained 
with hematoxylin then scored by an anatomopathologist 
(NM, FPL, or AC). The levels of staining were scored 
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based on staining intensity within the tumor sample, with 
weak as 1, moderate as 2, strong as 3.
Immunofluorescence assay
Cells were seeded on 12 mm-diameter glass slides 
for 24 hours, fixed in 5% paraformaldehyde for 1 hour 
at room temperature, permeabilized in PBS /0.5% Triton 
X-100 for 30 min and saturated for 20 min in PBS+ 
(1:100 (m/v) BSA, 1:250 (v/v) cold fish skin gelatin in 
PBS 1X, pH 8.0). Cells were then incubated overnight at 
4°C with the primary antibody diluted to 1:100 in PBS 
0.1% Triton X-100. NTS immunoreactivity was detected 
using a rabbit polyclonal anti-NTS immunoglobulin 
(NA1230, Tebu-Bio) and NTSR1 with a goat polyclonal 
antibody directed against the human COOH terminus of 
the receptor (C20, Santa Cruz Biotechnology). Slides were 
incubated for 1 hour with a fluorescent secondary antibody 
(1:100): a cyanin3 anti-rabbit immunoglobulin or a FITC-
coupled anti-rabbit or goat immunoglobulin (Jackson 
ImmunoResearch). Nuclei were counterstained for 5 min 
with DAPI 1:50000.
GRANT SUPPORT AND 
ACKNOWLEDGEMENTS
This work has been supported by INSERM, ANR-
10-INTB-1503 NTS-Polyplex and CARDIF grants; SD 
was supported by the “Ligue contre le cancer”. VKD 
was recipient of Vietnamese government fellowship. 
We thank Dr Neil Insdorf for his kind help in editing 
the manuscript. We also thank Sylvie Dumont for her 
excellent assistance with the immunohistochemistry. We 
thank Dr Helene Blons for checking for EGFR, HER2 and 
KRAS mutations.
The authors declare that they have no competing 
interests
SD, VKD, ZW, JL Carried out the experiments
NM, analyzed the mouse tissues
ODW, performed the invasion assay
FPL, AC provided the human tissues and 
participated in the design of the clinical part of the study
AK collected the tissue, set up the TMA, and 
provided the clinical information
AG, PF conceived of the study
All the authors meet the authorship requirements, 
and have read and approved the manuscript.
REFERENCES
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and 
Forman D. Global cancer statistics. CA Cancer J.Clin. 
2011; 61(2):69–90.
2. Siegel R, Naishadham D and Jemal A. Cancer statistics, 
2013. CA Cancer J.Clin. 2013; 63(1):11–30.
3. Dean-Colomb W and Esteva FJ. Her2-positive breast 
cancer: herceptin and beyond. Eur.J.Cancer. 2008; 
44(18):2806–2812.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and 
McGuire WL. Human breast cancer: correlation of relapse 
and survival with amplification of the HER-2/neu oncogene. 
Science. 1987; 235(4785):177–182.
5. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, 
Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fu-
moleau P and Gianni L. Phase II trial of pertuzumab and 
trastuzumab in patients with human epidermal growth fac-
tor receptor 2-positive metastatic breast cancer that pro-
gressed during prior trastuzumab therapy. J.Clin.Oncol. 
2010; 28(7):1138–1144.
6. Giltnane JM, Moeder CB, Camp RL and Rimm DL. Quan-
titative multiplexed analysis of ErbB family coexpression 
for primary breast cancer prognosis in a large retrospective 
cohort. Cancer. 2009; 115(11):2400–2409.
7. Spears M, Taylor KJ, Munro AF, Cunningham CA, Mallon 
EA, Twelves CJ, Cameron DA, Thomas J and Bartlett JM. 
In situ detection of HER2:HER2 and HER2:HER3 protein-
protein interactions demonstrates prognostic significance 
in early breast cancer. Breast Cancer Res.Treat. 2012; 
132(2):463–470.
8. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pan-
diella A and Amir E. HER3 overexpression and survival 
in solid tumors: a meta-analysis. J.Natl.Cancer Inst. 2013; 
105(4):266–273.
9. Valachis A, Nearchou A, Lind P and Mauri D. Lapatinib, 
trastuzumab or the combination added to preoperative che-
motherapy for breast cancer: a meta-analysis of randomized 
evidence. Breast Cancer Res.Treat. 2012; 135(3):655–662.
10. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM 
and Sliwkowski MX. Insights into ErbB signaling from the 
structure of the ErbB2-pertuzumab complex. Cancer Cell. 
2004; 5(4):317–328.
11. Dupouy S, Mourra N, Doan VK, Gompel A, Alifano M and 
Forgez P. The potential use of the neurotensin high affinity 
receptor 1 as a biomarker for cancer progression and as a 
component of personalized medicine in selective cancers. 
Biochimie. 2011; 93(9):1369–1378.
12. Wu Z, Martinez-Fong D, Tredaniel J and Forgez P. 
Neurotensin and its high affinity receptor 1 as a potential 
pharmacological target in cancer therapy. Front Endocrinol.
(Lausanne). 2012; 3(184).
13. Melander O, Maisel AS, Almgren P, Manjer J, Belting M, 
Hedblad B, Engstrom G, Kilger U, Nilsson P, Bergmann 
A and Orho-Melander M. Plasma proneurotensin and 
incidence of diabetes, cardiovascular disease, breast cancer, 
and mortality. JAMA. 2012; 308(14):1469–1475.
Oncotarget16www.impactjournals.com/oncotarget
14. Dupouy S, Viardot-Foucault V, Alifano M, Souaze F, 
Plu-Bureau , Chaouat M, Lavaur A, Hugol D, Gespach 
C, Gompel A and Forgez P. The neurotensin receptor-1 
pathway contributes to human ductal breast cancer 
progression. PLoS.One. 2009; 4(1):e4223.
15. Somai S, Gompel A, Rostene W and Forgez P. Neurotensin 
counteracts apoptosis in breast cancer cells. Biochem.
Biophys.Res.Commun. 2002; 295(2):482–488.
16. Souaze F, Dupouy S, Viardot-Foucault V, Bruyneel E, 
Attoub S, Gespach C, Gompel A and Forgez P. Expression 
of neurotensin and NT1 receptor in human breast cancer: 
a potential role in tumor progression. Cancer Res. 2006; 
66(12):6243–6249.
17. Rosell S, Thor K, Rokaeus A, Nyquist O, Lewenhaupt 
A, Kager L and Folkers K. Plasma concentration of 
neurotensin-like immunoreactivity (NTLI) and lower 
esophageal sphincter (LES) pressure in man following 
infusion of (Gln4)-neurotensin. Acta Physiol Scand. 1980; 
109(4):369–375.
18. Carraway R and Leeman SE. The isolation of a new 
hypotensive peptide, neurotensin, from bovine hypothalami. 
J.Biol.Chem. 1973; 248(19):6854–6861.
19. Reinecke M. Neurotensin. Immunohistochemical 
localization in central and peripheral nervous system and in 
endocrine cells and its functional role as neurotransmitter 
and endocrine hormone. Prog.Histochem.Cytochem. 1985; 
16(1):1–172.
20. White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, 
Gvozdenovic-Jeremic J, Shah P, Shiloach J, Tate CG and 
Grisshammer R. Structure of the agonist-bound neurotensin 
receptor. Nature. 2012; 490(7421):508–513.
21. Amorino GP, Deeble PD and Parsons SJ. Neurotensin 
stimulates mitogenesis of prostate cancer cells through 
a novel c-Src/Stat5b pathway. Oncogene. 2007; 26(5): 
745–756.
22. Zhao D, Zhan Y, Zeng H, Koon HW, Moyer MP and 
Pothoulakis C. Neurotensin stimulates expression of 
early growth response gene-1 and EGF receptor through 
MAP kinase activation in human colonic epithelial cells. 
Int.J.Cancer. 2007; 120(8):1652–1656.
23. Muller KM, Tveteraas IH, Aasrum M, Odegard J, Dawood 
M, Dajani O, Christoffersen T and Sandnes DL. Role of 
protein kinase C and epidermal growth factor receptor 
signalling in growth stimulation by neurotensin in colon 
carcinoma cells. BMC.Cancer. 2011; 11(421).
24. Mei ZB, Zhang ZJ, Liu CY, Liu Y, Cui A, Liang ZL, Wang 
GH and Cui L. Survival benefits of metformin for colorectal 
cancer patients with diabetes: a systematic review and meta-
analysis. PLoS.ONE. 2014; 9(3):e91818.
25. Kisfalvi K, Eibl G, Sinnett-Smith J and Rozengurt E. 
Metformin disrupts crosstalk between G protein-coupled 
receptor and insulin receptor signaling systems and inhibits 
pancreatic cancer growth. Cancer Res. 2009; 69(16):6539–
6545.
26. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J and Rozengurt 
E. Different patterns of Akt and ERK feedback activation 
in response to rapamycin, active-site mTOR inhibitors and 
metformin in pancreatic cancer cells. PLoS.One. 2013; 
8(2):e57289.
27. Alifano M, Souaze F, Dupouy S, Camilleri-Broet S, Younes 
M, hmed-Zaid SM, Takahashi T, Cancellieri A, Damiani S, 
Boaron M, Broet P, Miller LD, Gespach C, Regnard JF and 
Forgez P. Neurotensin receptor 1 determines the outcome 
of non-small cell lung cancer. Clin.Cancer Res. 2010; 
16(17):4401–4410.
28. Hasegawa K and Carr BI. Neurotensin-amplification of 
DNA synthesis stimulated by EGF or TGF alpha in primary 
cultures of adult rat hepatocytes. Cell Struct.Funct. 1993; 
18(2):105–110.
29. Olsen DA, Bechmann T, Ostergaard B, Wamberg PA, 
Jakobsen EH and Brandslund I. Increased concentrations of 
growth factors and activation of the EGFR system in breast 
cancer. Clin.Chem.Lab Med. 2012; 50(10):1809–1818.
30. Wiley HS. Anomalous binding of epidermal growth factor 
to A431 cells is due to the effect of high receptor densities 
and a saturable endocytic system. J.Cell Biol. 1988; 
107(2):801–810.
31. Jiang X and Sorkin A. Epidermal growth factor receptor 
internalization through clathrin-coated pits requires Cbl 
RING finger and proline-rich domains but not receptor 
polyubiquitylation. Traffic. 2003; 4(8):529–543.
32. Beguinot L, Lyall RM, Willingham MC and Pastan I. 
Down-regulation of the epidermal growth factor receptor in 
KB cells is due to receptor internalization and subsequent 
degradation in lysosomes. Proc.Natl.Acad.Sci.U.S.A. 1984; 
81(8):2384–2388.
33. Stoscheck CM and Carpenter G. Characterization of the 
metabolic turnover of epidermal growth factor receptor 
protein in A-431 cells. J.Cell Physiol. 1984; 120(3): 
296–302.
34. Wang Z, Zhang L, Yeung TK and Chen X. Endocytosis 
deficiency of epidermal growth factor (EGF) receptor-
ErbB2 heterodimers in response to EGF stimulation. Mol.
Biol.Cell. 1999; 10(5):1621–1636.
35. Kornilova ES, Taverna D, Hoeck W and Hynes NE. Surface 
expression of erbB-2 protein is post-transcriptionally 
regulated in mammary epithelial cells by epidermal 
growth factor and by the culture density. Oncogene. 1992; 
7(3):511–519.
36. Haslekas C, Breen K, Pedersen KW, Johannessen LE, 
Stang E and Madshus IH. The inhibitory effect of ErbB2 
on epidermal growth factor-induced formation of clathrin-
coated pits correlates with retention of epidermal growth 
factor receptor-ErbB2 oligomeric complexes at the plasma 
membrane. Mol.Biol.Cell. 2005; 16(12):5832–5842.
37. Hartman Z, Zhao H and Agazie YM. HER2 stabilizes 
EGFR and itself by altering autophosphorylation patterns 
in a manner that overcomes regulatory mechanisms and 
Oncotarget17www.impactjournals.com/oncotarget
promotes proliferative and transformation signaling. 
Oncogene. 2013; 32(35):4169–4180.
38. Offterdinger M and Bastiaens PI. Prolonged EGFR 
signaling by ERBB2-mediated sequestration at the plasma 
membrane. Traffic. 2008; 9(1):147–155.
39. Worthylake R, Opresko LK and Wiley HS. ErbB-
2 amplification inhibits down-regulation and induces 
constitutive activation of both ErbB-2 and epidermal growth 
factor receptors. J.Biol.Chem. 1999; 274(13):8865–8874.
40. Baulida J, Kraus MH, Alimandi M, Di Fiore PP and 
Carpenter G. All ErbB receptors other than the epidermal 
growth factor receptor are endocytosis impaired. J.Biol.
Chem. 1996; 271(9):5251–5257.
41. Waterman H, Alroy I, Strano S, Seger R and Yarden Y. 
The C-terminus of the kinase-defective neuregulin receptor 
ErbB-3 confers mitogenic superiority and dictates endocytic 
routing. EMBO J. 1999; 18(12):3348–3358.
42. Waterman H, Sabanai I, Geiger B and Yarden Y. 
Alternative intracellular routing of ErbB receptors 
may determine signaling potency. J.Biol.Chem. 1998; 
273(22):13819–13827.
43. Marshall C, Blackburn E, Clark M, Humphreys S and 
Gullick WJ. Neuregulins 1-4 are expressed in the cytoplasm 
or nuclei of ductal carcinoma (in situ) of the human breast. 
Breast Cancer Res.Treat. 2006; 96(2):163–168.
44. Dunn M, Sinha P, Campbell R, Blackburn E, Levinson N, 
Rampaul R, Bates T, Humphreys S and Gullick WJ. Co-
expression of neuregulins 1, 2, 3 and 4 in human breast 
cancer. J.Pathol. 2004; 203(2):672–680.
45. Klubo-Gwiezdzinska J, Jensen K, Costello J, Patel A, 
Hoperia V, Bauer A, Burman KD, Wartofsky L and Vasko 
V. Metformin inhibits growth and decreases resistance to 
anoikis in medullary thyroid cancer cells. Endocr.Relat 
Cancer. 2012; 19(3):447–456.
46. Toy-Miou-Leong M, Cortes CL, Beaudet A, Rostene W and 
Forgez P. Receptor trafficking via the perinuclear recycling 
compartment accompanied by cell division is necessary 
for permanent neurotensin cell sensitization and leads to 
chronic mitogen-activated protein kinase activation. J.Biol.
Chem. 2004; 279(13):12636–12646.
47. Dupouy S, Mourra N, Doan VK, Gompel A, Alifano M and 
Forgez P. The potential use of the neurotensin high affinity 
receptor 1 as a biomarker for cancer progression and as a 
component of personalized medicine in selective cancers. 
Biochimie. 2011; 93(9):1369–1378.
48. De Wever O, Hendrix A, De BA, Westbroek W, Braems G, 
Emami S, Sabbah M, Gespach C and Bracke M. Modeling 
and quantification of cancer cell invasion through collagen 
type I matrices. Int.J.Dev.Biol. 2010; 54(5):887–896.
49. Chirgwin JM, Przybyla AE, MacDonald RJ and Rutter 
WJ. Isolation of biologically active ribonucleic acid from 
sources enriched in ribonuclease. Biochemistry. 1979; 
18(24):5294–5299.
50. Souaze F, Rostene W and Forgez P. Neurotensin agonist 
induces differential regulation of neurotensin receptor 
mRNA. Identification of distinct transcriptional and 
post-transcriptional mechanisms. J.Biol.Chem. 1997; 
272(15):10087–10094.
51. Younes M, Dupouy S, Wu Z, Lupo AM, Mourra N, 
Takahashi T, Flejou J, Trédaniel J, Régnard JF, Damotte D, 
Alifano M, Forgez P. Oncotarget.2014; in press.
